June 23, 2010 (FinancialWire) (Go to http://www.financialwire.net/?s=ftrdnwswnd for all of today’s featured news.) — Sunridge International (SNDZ.OB) said it has signed an exclusive contract with New Amsterdam Marketing Corp. to distribute the company's PNT non-invasive glaucoma treatment in India.  The five-year contract is valued at several million dollars.

Sunridge CEO, G. Richard Smith said, "We are introducing our PNT equipment and treatment in a number of markets around the world but India is a very special place, which we feel offers enormous opportunity for us.”

PNT is a two-minute, non-invasive treatment for glaucoma. The treatment only needs to be performed 3-4 times a year, allowing rural areas a treatment regime that might not otherwise be available to them, according to Sunridge.

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide.

Arizona-based Sunridge International is a holding company is focused on strategic acquisitions of vertically integrated companies in the private sector.

The firm’s wholly owned subsidiary, Ophthalmic International, is a manufacturer of medical products with offices located near Phoenix, Arizona and Rome, Italy.

OI has developed a patented alternative treatment for glaucoma and ocular hypertension, known as Pneumatic Trabeculoplasty.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://investrend.stocksmart.com/ss/html/hpcompany.html). Current valuation analysis research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public other companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation from subject entities, companies, equities, or representatives thereof, for its news, opinions or distributions. Further disclosure is posted at the FinancialWire(tm) website (at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Copyright © MMX, FinancialWire(tm); All rights reserved.

[hlmsmlh] [biomedphrm] [nwdlsldw] [ntrntnlcmpnsbsnss] [nnddadn] [ftrdnwswnd]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.